<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274195</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCH-SCT -1001</org_study_id>
    <nct_id>NCT01274195</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we plan to improve the outcome of hematopoietic stem cell transplantation by
      using optimal busulfan dose through pharmacokinetic study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Busulfan is a highly toxic drug with narrow therapeutic window used for the conditioning of
      hematopoietic stem cell transplantation. High exposure is associated with systemic toxicity
      such as veno-occlusive disease (VOD) and underexposure is associated with graft failure or
      relapse. In this study the investigators plan to improve the outcome of hematopoietic stem
      cell transplantation by using optimal busulfan dose through pharmacokinetic study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate 1-year event free survival after hematopoietic stem cell transplantation.</measure>
    <time_frame>For 4 days used Buslufan through pharmacokinetic study in hematopoietic stem cell transplantation</time_frame>
    <description>To evaluate 1-year event free survival after hematopoietic stem cell transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate engraftment rate, toxicities associated with hematopoietic stem cell transplantation, acute and chronic GVHD, treatment related mortality and relapse rate.</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
    <description>To evaluate engraftment rate, toxicities associated with hematopoietic stem cell transplantation, acute and chronic GVHD, treatment related mortality and relapse rate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Busulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>First dose: busulfan (120 mg/m2 ivs once daily) (if age&lt;1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study</description>
    <arm_group_label>Busulfan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are diagnosed as AML.

          2. Patients who need hematopoietic stem cell transplantation with busulfan based
             conditioning regimen.

          3. Age: up to 21 years

          4. Performance status: ECOG 0-2.

          5. Patients must be free of significant functional deficits in major organs, but the
             following eligibility criteria may be modified in individual cases. 1. Heart: a
             shortening fraction &gt; 30% and ejection fraction &gt; 45%. 2. Liver: total bilirubin &lt; 2 ×
             upper limit of normal; ALT &lt; 3 × upper limit of normal. 3. Kidney: creatinine &lt;2 ×
             normal or a creatinine clearance (GFR) &gt; 60 ml/min/1.73m2.

          6. Patients must lack any active viral infections or active fungal infection.

          7. Appropriate donor is available: Matched in 6/6 of A, B, DR loci.

          8. Patients (or one of parents if patients age &lt; 20) should sign informed consent.

        Exclusion Criteria:

          1. Pregnant or nursing women.

          2. Malignant or nonmalignant illness that is uncontrolled or whose control may be
             jeopardized by complications of study therapy.

          3. Psychiatric disorder that would preclude compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, MD, PhD</last_name>
    <phone>82 2 2072 0177</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Won Lee, MD</last_name>
    <phone>82 2 2072 0177</phone>
    <email>agnesjw@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Daehangno, Jongno-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, MD, PhD</last_name>
      <phone>82 2 2072 0177</phone>
      <email>kanghj@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji Won Lee, MD</last_name>
      <phone>82 2 2072 0177</phone>
      <email>agnesjw@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Hyo Seop Ahn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>November 17, 2013</last_update_submitted>
  <last_update_submitted_qc>November 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

